Dermbits

Welcome to Dermbits! Watch short videos of KOLs answering your questions

Dr Lewitt on Psoriasis (September 2026)

Are there patients who technically qualify for more aggressive therapy but whom you still consider for apremilast? Why?

Sep 1, 2026Psoriasis

Are there patients who technically qualify for more aggressive therapy but whom you still consider for apremilast? Why?

-

How do you determine whether a patient is benefiting enough from apremilast to continue therapy rather than pursue a different option?

Sep 1, 2026Psoriasis

How do you determine whether a patient is benefiting enough from apremilast to continue therapy rather than pursue a different option?

-

What factors make you comfortable continuing apremilast in a patient who has improved but not achieved complete clearance?

Sep 1, 2026Psoriasis

What factors make you comfortable continuing apremilast in a patient who has improved but not achieved complete clearance?

-

Have you found that patient satisfaction and clinical response always align when evaluating treatment success with apremilast?

Sep 1, 2026Psoriasis

Have you found that patient satisfaction and clinical response always align when evaluating treatment success with apremilast?

-

When patients and clinicians define treatment success for psoriasis differently, how do you navigate those conversations?

Sep 1, 2026Psoriasis

When patients and clinicians define treatment success for psoriasis differently, how do you navigate those conversations?

-

How do you decide when a chronic disease is well controlled enough versus when additional improvement should still be pursued?

Sep 1, 2026Psoriasis

How do you decide when a chronic disease is well controlled enough versus when additional improvement should still be pursued?

-